A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of JNJ-64991524 in Healthy Participants

Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of JNJ-64991524 in Healthy Participants

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Apr 2018

At a glance

  • Drugs JNJ-64991524 (Primary)
  • Indications Unspecified
  • Focus Adverse reactions
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 05 Apr 2018 Planned number of patients changed from 96 to 84.
    • 05 Apr 2018 Planned End Date changed from 28 Dec 2018 to 21 Nov 2018.
    • 22 Feb 2018 Planned End Date changed from 31 Oct 2018 to 28 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top